Scribe Therapeutics Inc. Common Stock (SCTX) — Cash Flow-to-Debt Ratio
Scribe Therapeutics Inc. Common Stock (SCTX) has a Cash Flow-to-Debt Ratio of -0.03x as of March 2026, meaning its operating cash flow of $-7.55 Million could theoretically repay 0% of its total liabilities ($223.95 Million) in one year. For the full cash flow conversion analysis, see cash efficiency ratio of Scribe Therapeutics Inc. Common Stock.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Scribe Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Scribe Therapeutics Inc. Common Stock across 2 annual periods. See Scribe Therapeutics Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Scribe Therapeutics Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Scribe Therapeutics Inc. Common Stock. See working capital position of Scribe Therapeutics Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.20x | $-45.21 Million | $221.64 Million | ▼ -14.5% |
| 2024 | -0.18x | $-45.23 Million | $253.83 Million | — |